• Nyrada Inc. receives notice of allowance for Xolatryp US patent
• Patent covers Xolatryp's chemical structure
• Strengthens Nyrada's intellectual property protection
• Phase IIa clinical trial for Xolatryp has commenced

Nyrada Inc. (ASX:NYR) announced receipt of a Notice of Allowance from the US Patent and Trademark Office for its patent application covering the composition of matter of Xolatryp. This patent, subject to the payment of the issue fee, will provide intellectual property protection within the United States over Xolatryp's chemical structure, with a 20-year term from the September 2024 filing date. The composition of matter patent protects against unauthorized manufacture, use, sale, or import of Xolatryp without Nyrada's approval. The US application forms part of a broader global patent portfolio filed by the Company across key jurisdictions including Australia, Europe, and Japan. Nyrada CEO and Managing Director James Bonnar commented on the significance of this milestone, emphasizing the importance of robust intellectual property protection in realizing the full commercial value of Xolatryp.

null

null